Collectively, our results suggest that the antitumor effects induced by fosaprepitant in neuroblastoma cells may be due, at least in part, to decreased SRC phosphorylation leading to downstream E2F2 repression and that apoptosis might be induced via activation of pro-apoptotic TP53 signaling. The gene discussed is TP53; the disease is neuroblastoma.